Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.53 |
| ▸ | CNR1 | P21554 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13257169 | 0.96 | CNR2 (0.53) | CNR2CNR1ALDH1A1CYP2C8CYP2C9 | |
| SCHEMBL9892838 | 0.94 | ALDH1A1 (0.56) | CNR2CNR1ALDH1A1CYP2C8CYP2C9 | |
| SCHEMBL9893144 | 0.83 | MAPK14 (0.46) | CNR2CNR1MAPK14 | |
| SCHEMBL9893147 | 0.79 | CNR2 (0.53) | CNR2CNR1ALDH1A1CYP2C8CYP2C9 | |
| SCHEMBL2567009 | 0.79 | CNR2 (0.52) | CNR2CNR1ALDH1A1CYP2C8CYP2C9 | |
| SCHEMBL9892286 | 0.79 | CNR2 (0.53) | CNR2CNR1ALDH1A1CYP2C8CYP2C9 | |
| SCHEMBL9892840 | 0.79 | CNR2 (0.57) | CNR2CNR1ALDH1A1 | |
| SCHEMBL13284926 | 0.79 | NPC1 (0.60) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL2569404 | 0.79 | NPC1 (0.60) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL13257172 | 0.78 | CNR2 (0.49) | CNR2ALDH1A1CYP2C9MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-2384320-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-11-09 | — | — | EP | disclosed |
| WO-2010077836-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885ALDH1A1 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.